ANIX · NASDAQ
Anixa Biosciences (ANIX) Stock Price & Fundamentals
Anixa Biosciences (ANIX) closed at $519.81 on Oct 9, 2026, down 1.09% from the previous close of $525.54.
Share price, past year
1Y +4.11%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $519.81 |
| Sep 30, 2026 | $525.70 |
| Aug 31, 2026 | $539.00 |
| Jul 31, 2026 | $518.61 |
| Jun 30, 2026 | $488.88 |
| May 29, 2026 | $512.29 |
| Apr 30, 2026 | $501.36 |
| Mar 31, 2026 | $516.88 |
| Feb 27, 2026 | $488.09 |
| Jan 30, 2026 | $473.45 |
| Dec 31, 2025 | $449.47 |
| Nov 28, 2025 | $471.34 |
| Oct 31, 2025 | $478.20 |
Key statistics
- Market cap
- $17.98B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.31
- Revenue (TTM)
- —
- Net income (TTM)
- −$10.38M
- Shares outstanding
- 34.6M
- Dividend yield
- —
- 52-week range
- $440.08 – $548.56
Anixa Biosciences's market cap is $17.98B, based on a share price of $519.81 and 34.6M shares outstanding as of Jul 31, 2026.
Financials
Anixa Biosciences reported revenue of $210.00K for fiscal 2024, unchanged 0.00% from fiscal 2023.
Anixa Biosciences reported a net loss of $10.93M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Oct 31, 2024 | $210.00K | 0.0% | −$12.55M | −5,978.1% | −$0.39 | — |
| FY2023ended Oct 31, 2023 | $210.00K | −59.0% | −$9.81M | −4,671.9% | −$0.32 | — |
| FY2021ended Oct 31, 2021 | $512.00K | +104.8% | −$12.95M | −2,530.1% | −$0.45 | — |
| FY2019ended Oct 31, 2019 | $250.00K | −77.5% | −$11.65M | −4,658.8% | −$0.59 | −$4.92M |
| FY2018ended Oct 31, 2018 | $1.11M | +206.9% | −$14.00M | −1,258.1% | −$0.79 | −$4.31M |
| FY2017ended Oct 31, 2017 | $362.50K | +20.8% | −$5.01M | −1,381.8% | −$0.58 | −$3.83M |
| FY2016ended Oct 31, 2016 | $300.00K | −96.8% | −$5.02M | −1,672.1% | −$0.57 | −$3.53M |
| FY2015ended Oct 31, 2015 | $9.26M | +152.4% | — | — | — | $1.31M |
| FY2014ended Oct 31, 2014 | $3.67M | +843.1% | — | — | — | −$2.39M |
| FY2013ended Oct 31, 2013 | $388.85K | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2023ended Apr 30, 2023 | $210.00K | — | — |
| Q1 FY2022ended Jan 31, 2022 | $513.00K | — | — |
| Q1 FY2021ended Jan 31, 2021 | $512.50K | — | — |
| Q2 FY2019ended Apr 30, 2019 | $250.00K | — | — |
| Q3 FY2018ended Jul 31, 2018 | $362.50K | — | — |
| Q2 FY2018ended Apr 30, 2018 | $750.00K | — | — |
| Q3 FY2017ended Jul 31, 2017 | $362.50K | — | — |
| Q3 FY2016ended Jul 31, 2016 | $100.00K | — | — |
Company profile
- Name
- Anixa Biosciences Inc
- Ticker
- ANIX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 3150 Almaden Expressway, Suite 250, San Jose, CA 95118
- Incorporated in
- DE
- Fiscal year ends
- October
- SEC CIK
- 0000715446
Recent SEC filings
- Sep 9, 2026
- Jun 10, 2026
- Mar 11, 2026
- Mar 9, 2026
- Feb 9, 2026
- Jan 12, 2026
- Dec 12, 2025
- Sep 10, 2025
Frequently asked questions
What is Anixa Biosciences's stock price?
Anixa Biosciences (ANIX) closed at $519.81 on Oct 9, 2026, down 1.09% from the previous close of $525.54.
What is Anixa Biosciences's market cap?
Anixa Biosciences's market cap is $17.98B, based on a share price of $519.81 and 34.6M shares outstanding as of Jul 31, 2026.
How much revenue does Anixa Biosciences make?
Anixa Biosciences reported revenue of $210.00K for fiscal 2024, unchanged 0.00% from fiscal 2023.
Does Anixa Biosciences pay a dividend?
Anixa Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Anixa Biosciences Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures